- Products & Solutions
- FDA IVD
- About Us
- News & Events
- Contact
- Additional Sites
BUHLMANN News
Visit BUHLMANN at DDW 2022
Assays Offerings Assays Offerings: We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United ...
Buhlmann – Next Generation Food Allergy Drug Development Summit
Next Generation Food Allergy Drug Development Summit, July 20-22, 2021: BUHLMANN is proud to partner with this event, specifically focused ...
BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics
Announcement BUHLMANN Diagnostic Corp is pleased to announce a new partner channel agreement with Roche Diagnostics for the launch and ...
Educational Webinar recording from AMLI presentation by Dr Arne Roseth
BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a ...
Use of basophil activation in oral immunotherapy
New JACI paper from Patil et al: Food allergy is a growing public health burden in children and adults all ...
CALEX Cap Promotion
BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an ...
Flow CAST- Assay Overview Video
Flow CAST®: Research Use Only in the US. Not for diagnostic procedures. Health Canada License:101781 BÜHLMANN Flow CAST® and Basophil ...
IBDoc Key Literature List
IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters ...
